Anlotinib treatment for rapidly progressing pediatric embryonal rhabdomyosarcoma in the maxillary gingiva: a case report.
Anlotinib
Chemotherapy
Embryonal rhabdomyosarcoma
Maxillary gingiva
Tyrosine kinase inhibitor
Journal
Diagnostic pathology
ISSN: 1746-1596
Titre abrégé: Diagn Pathol
Pays: England
ID NLM: 101251558
Informations de publication
Date de publication:
08 Oct 2024
08 Oct 2024
Historique:
received:
03
07
2024
accepted:
22
09
2024
medline:
9
10
2024
pubmed:
9
10
2024
entrez:
8
10
2024
Statut:
epublish
Résumé
Embryonal rhabdomyosarcoma (ERMS) is a highly aggressive form of soft-tissue sarcoma that predominantly affects children. Due to limited benefits and resistance to therapy, there is an unmet need to explore alternative therapeutic strategies. In this report, we present a rare case of pediatric ERMS located on the right side of the maxillary gingiva. A composite reference guide integrating clinical, radiographic, and histopathologic findings was used for a definitive diagnosis. Targeted next-generation sequencing of tumor biopsy was performed to identify genetic alterations. A 12-year-old female was admitted to the Pediatric Intensive Care Unit (PICU) and underwent a tracheotomy to relieve asphyxiation caused by a 5.5 cm diameter mass compressing the tongue root and pharyngeal cavity. Hematoxylin and eosin staining revealed a hybrid morphology characterized by clusters of round and spindle cells. Further immunohistochemistry assays indicated positive immunoreactivity for desmin, myogenin, and MyoD1. Various genetic alterations were identified, including mutations in GNAS, HRAS, LRP1B, amplification of MDM2 and IGF1R, and two novel IGF1R fusions. Negative PAX-FOXO1 fusion status supported the clinical diagnosis of ERMS. Initial treatment involved standard chemotherapy; however, the tumor persisted in its growth, reaching a maximum volume of 12 cm × 6 cm × 4 cm by the completion of treatment. Subsequent oral administration of anlotinib yielded a significant antitumor response, characterized by substantial tumor necrosis and size reduction. Following the ligation of the tumor pedicle and its removal, the patient developed a stabilized condition and was successfully discharged from PICU. Our study highlights the importance of accurate diagnosis established on multifaceted assessment for the effective treatment of ERMS. We present compelling evidence supporting the clinical use of anlotinib as a promising treatment strategy for pediatric ERMS patients, especially for those resistant to conventional chemotherapy.
Sections du résumé
BACKGROUND
BACKGROUND
Embryonal rhabdomyosarcoma (ERMS) is a highly aggressive form of soft-tissue sarcoma that predominantly affects children. Due to limited benefits and resistance to therapy, there is an unmet need to explore alternative therapeutic strategies.
CASE PRESENTATION
METHODS
In this report, we present a rare case of pediatric ERMS located on the right side of the maxillary gingiva. A composite reference guide integrating clinical, radiographic, and histopathologic findings was used for a definitive diagnosis. Targeted next-generation sequencing of tumor biopsy was performed to identify genetic alterations. A 12-year-old female was admitted to the Pediatric Intensive Care Unit (PICU) and underwent a tracheotomy to relieve asphyxiation caused by a 5.5 cm diameter mass compressing the tongue root and pharyngeal cavity. Hematoxylin and eosin staining revealed a hybrid morphology characterized by clusters of round and spindle cells. Further immunohistochemistry assays indicated positive immunoreactivity for desmin, myogenin, and MyoD1. Various genetic alterations were identified, including mutations in GNAS, HRAS, LRP1B, amplification of MDM2 and IGF1R, and two novel IGF1R fusions. Negative PAX-FOXO1 fusion status supported the clinical diagnosis of ERMS. Initial treatment involved standard chemotherapy; however, the tumor persisted in its growth, reaching a maximum volume of 12 cm × 6 cm × 4 cm by the completion of treatment. Subsequent oral administration of anlotinib yielded a significant antitumor response, characterized by substantial tumor necrosis and size reduction. Following the ligation of the tumor pedicle and its removal, the patient developed a stabilized condition and was successfully discharged from PICU.
CONCLUSIONS
CONCLUSIONS
Our study highlights the importance of accurate diagnosis established on multifaceted assessment for the effective treatment of ERMS. We present compelling evidence supporting the clinical use of anlotinib as a promising treatment strategy for pediatric ERMS patients, especially for those resistant to conventional chemotherapy.
Identifiants
pubmed: 39379998
doi: 10.1186/s13000-024-01555-5
pii: 10.1186/s13000-024-01555-5
doi:
Substances chimiques
anlotinib
0
Quinolines
0
Indoles
0
Antineoplastic Agents
0
Biomarkers, Tumor
0
Types de publication
Case Reports
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
135Informations de copyright
© 2024. The Author(s).
Références
Skapek Stephen X, Ferrari Andrea, Gupta Abha A, Lupo Philip J, Butler Erin S, Janet, et al. Rhabdomyosarcoma Nat Reviews Disease Primers. 2019;5(1):1.
doi: 10.1038/s41572-018-0051-2
pubmed: 30617281
Nangalia Richa S, Neha SM, Abdul, Mousumi P. Rhabdomyosarcoma involving Maxilla mimicking gingival enlargement: a diagnostic challenge. BMJ Case Rep CP. 2019;12(11):e230692.
doi: 10.1136/bcr-2019-230692
Bansal A, Goyal S, Goyal A, Jana M. WHO classification of soft tissue tumours 2020: an update and simplified approach for radiologists. Eur J Radiol. 2021;143:109937.
doi: 10.1016/j.ejrad.2021.109937
pubmed: 34547634
Loeb D.M., Thornton K., Shokek O. Pediatric soft tissue sarcomas. Surg Clin North Am. 2008;88(3):615–27. vii.
Rong Fan DM, Parham LL, Wang. An Integrative Morphologic and Molecular Approach for Diagnosis and subclassification of Rhabdomyosarcoma. Arch Pathol Lab Med. 2022;146(8):953–9.
doi: 10.5858/arpa.2021-0183-RA
pubmed: 35051261
Morotti RA, Nicol KK, Parham DM, Teot LA, Moore J, Hayes J, et al. An immunohistochemical algorithm to facilitate diagnosis and subtyping of rhabdomyosarcoma: the children’s Oncology Group experience. Am J Surg Pathol. 2006;30(8):962–8.
doi: 10.1097/00000478-200608000-00005
pubmed: 16861966
Han B, Li K, Zhao Y, Li B, Cheng Y, Zhou J, et al. Anlotinib as a third-line therapy in patients with refractory advanced non-small-cell lung cancer: a multicentre, randomised phase II trial (ALTER0302). Br J Cancer. 2018;118(5):654–61.
doi: 10.1038/bjc.2017.478
pubmed: 29438373
pmcid: 5846072
Perot G, Chibon F, Montero A, Lagarde P, de The H, Terrier P, et al. Constant p53 pathway inactivation in a large series of soft tissue sarcomas with complex genetics. Am J Pathol. 2010;177(4):2080–90.
doi: 10.2353/ajpath.2010.100104
pubmed: 20884963
pmcid: 2947301
Stratton MR, Fisher C, Gusterson BA, Cooper CS. Detection of point mutations in N-ras and K-ras genes of human embryonal rhabdomyosarcomas using oligonucleotide probes and the polymerase chain reaction. Cancer Res. 1989;49(22):6324–7.
pubmed: 2680062
Kohsaka S, Shukla N, Ameur N, Ito T, Ng CK, Wang L, et al. A recurrent neomorphic mutation in MYOD1 defines a clinically aggressive subset of embryonal rhabdomyosarcoma associated with PI3K-AKT pathway mutations. Nat Genet. 2014;46(6):595–600.
doi: 10.1038/ng.2969
pubmed: 24793135
pmcid: 4231202
Lee HW, Sa JK, Gualberto A, Scholz C, Sung HH, Jeong BC, et al. A phase II trial of Tipifarnib for patients with previously treated, metastatic urothelial carcinoma harboring HRAS mutations. Clin Cancer Res. 2020;26(19):5113–9.
doi: 10.1158/1078-0432.CCR-20-1246
pubmed: 32636318
Ho AL, Brana I, Haddad R, Bauman J, Bible K, Oosting S, et al. Tipifarnib in Head and Neck squamous cell carcinoma with HRAS mutations. J Clin Oncol. 2021;39(17):1856–64.
doi: 10.1200/JCO.20.02903
pubmed: 33750196
pmcid: 8189627
Taylor AC, Shu L, Danks MK, Poquette CA, Shetty S, Thayer MJ, et al. P53 mutation and MDM2 amplification frequency in pediatric rhabdomyosarcoma tumors and cell lines. Med Pediatr Oncol. 2000;35(2):96–103.
Bridge JA, Liu J, Qualman SJ, Suijkerbuijk R, Wenger G, Zhang J, et al. Genomic gains and losses are similar in genetic and histologic subsets of rhabdomyosarcoma, whereas amplification predominates in embryonal with anaplasia and alveolar subtypes. Genes Chromosomes Cancer. 2002;33(3):310–21.
doi: 10.1002/gcc.10026
pubmed: 11807989
Pollak M. Insulin and insulin-like growth factor signalling in neoplasia. Nat Rev Cancer. 2008;8(12):915–28.
doi: 10.1038/nrc2536
pubmed: 19029956
Weigel B, Malempati S, Reid JM, Voss SD, Cho SY, Chen HX, et al. Phase 2 trial of cixutumumab in children, adolescents, and young adults with refractory solid tumors: a report from the Children’s Oncology Group. Pediatr Blood Cancer. 2014;61(3):452–6.
doi: 10.1002/pbc.24605
pubmed: 23956055
Wagner LM, Fouladi M, Ahmed A, Krailo MD, Weigel B, DuBois SG, et al. Phase II study of cixutumumab in combination with temsirolimus in pediatric patients and young adults with recurrent or refractory sarcoma: a report from the Children’s Oncology Group. Pediatr Blood Cancer. 2015;62(3):440–4.
doi: 10.1002/pbc.25334
pubmed: 25446280
Chugh R, Griffith KA, Davis EJ, Thomas DG, Zavala JD, Metko G, et al. Doxorubicin plus the IGF-1R antibody cixutumumab in soft tissue sarcoma: a phase I study using the TITE-CRM model. Ann Oncol. 2015;26(7):1459–64.
doi: 10.1093/annonc/mdv171
pubmed: 25858498
pmcid: 4478972
Weigel SMB, Anderson JAMESR, Parham D, Teot LA, Rodeberg DA, Yock TI, Shulkin BL, Hawkins DS. Early results from Children’s Oncology Group (COG) ARST08P1: pilot studies of cixutumumab or temozolomide with intensive multiagent chemotherapy for patients with metastatic rhabdomyosarcoma (RMS). J Clin Oncol, 2015. 33: p. Number 15_suppl.
Lina Tang, Yonggang Wang, Jianjun Zhang, et al. Efficacy and safety of anlotinib in advanced soft tissue sarcoma: results from one of multi-centers in a phase IIB trial (ALTER0203). JCO. 2019;37:e22518. https://doi.org/10.1200/JCO.2019.37.15_suppl.e22518 .
Yao YCY, Wang S, Huang G, Cai Q, Shang G, Wang G, Qu G, Wu Q, Jiang Y, Song J, Chen J, Zhu X, Cai Z, Bai C, Lu Y, Yu Z. Jingnan Shen, and Jianqiang Cai, Anlotinib for metastasis soft tissue sarcoma: a randomized, double-blind, placebo-controlled and multi-centered clinical trial. JCO. 2018;36:11503–11503.
doi: 10.1200/JCO.2018.36.15_suppl.11503
Lu S, Hong Y, Chen H, Wu L, Sun F, Wang J, et al. The efficacy and safety of Anlotinib in Pediatric patients with refractory or recurrent solid tumors. Front Pharmacol. 2022;13:711704.
doi: 10.3389/fphar.2022.711704
pubmed: 35431969
pmcid: 9008584
Suying Lu, Juan Wang, Feifei Sun, et al. Phase I study of anlotinib in pediatric patients with high-risk, recurrent, or refractory sarcomas. JCO. 2023;41:e23538. https://doi.org/10.1200/JCO.2023.41.16_suppl.e23538 .
Liu Jiayong G, Tian T, Zhichao L, Shu X, Jie B, Chujie, et al. Phase II study of TQB2450, a novel PD-L1 antibody, in combination with anlotinib in patients with locally advanced or metastatic soft tissue sarcoma. Clin Cancer Res. 2022;28(16):3473–9.
pubmed: 35675031
pmcid: 9662895
Xiaogang S, Xinyu W, Jun Z, Yali X, Hao Z, Mian X et al. Next generation sequencing predicting clinical effect of immunotherapy on adult Rhabdomyosarcoma patient: a case report. Medicine, 2023. 102(21).